Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster III
Introduction: Ibrutinib (Ibr) is a small molecule that effectively targets B cell malignancies by inhibiting Bruton's tyrosine kinase activity (BTK). Clinical studies have shown a consistent increase in OS, PFS and response rate for relapsed-refractory CLL and mantle cell lymphoma (MCL) with variable cardiac toxicity (CT) (Table 1).
Methods: Retrospective analysis of pts treated at The Abramson Cancer Center at the University of Pennsylvania to identify the incidence and characteristics of Ibr related CT.
Results: We identified 32 pts treated with Ibr (87.6% CLL, 6.2 MCL, 6.2% other). The median age was 65 yrs (47-83). 53% of patients had a prior history of cardiovascular (CV) comorbidities: 16% hypertension (HTN), 3 % arrhythmia, 9% CAD, 0% with heart failure. During the course of therapy, we identified 11 pts (mean age 69.6 yrs; range 51-83) with presumed Ibr-induced CT: 5 with AF (16%), 4 patients with aggravation of pre-existing HTN (13%), 1 with sinus bradycardia (3%), and 1 with unexplained syncope (3%). 88% were male and all had at least one cardiac co-morbidity. The median time to onset of AF was 197 days (63-358) and acceleration of HTN 42 days (27-57). All of the HTN patients had pre-existing HTN and of the 5 pts with AF, 2 had a history of HTN, 2 PAF, and 3 CAD. All patients were co-managed by the treating oncologist and cardiologist. Successful management of CT did not require Ibr discontinuation in all pts. We observed no arrhythmia or treatment related embolic/bleeding events; AF pts were all anticoagulated (3% warfarin, 87% novel antithrombotic drug). In 2/5 AF pts, Ibr dose was reduced. BTK inhibition may induce unique CT by affecting the regulation of off target kinases with BTK selectivity (Table 2). Table 3 provides recommendations for management of Ibr related CT for the practicing oncologist.
Conclusions: We identified a 34% incidence of Ibr related CT. These results are unique in that we provide long-term follow up of such events and demonstrate that in practice, Ibr related CT can successfully be managed by the medical oncologist / cardio-oncology team. No pts discontinued Ibr in this series due to CT events. Pre-existing CV disease is a major risk factor for Ibr-related AF and HTN. The absence of cardiac co-morbidity may have negative predictive value. In conclusion, there is a potential for CT in elderly patients with pre-existing cardiac disease and HTN treated with Ibr. This suggests the need for proactive co-management of these patients with cardiologists trained in cardio-oncology.
Table 1: Reported CT among CLL/ mantle cell lymphoma pts | ||||
Cardiac Event
| CLL (Byrd, 2013)
| MCL (Wang, 2014)
| RESONATE (Byrd, 2014)
| Follow-up analysis (Byrd, 2015) |
AF
| 3 (4%)
| 5 (4.5%)
| 6 (3%)
| 8 (6%)
|
Peripheral edema
| 18 (21%)
| 3 (2.7%)
| 22 (11%)
| NA
|
Hypertension
| 5 (11%)
| NA
| NA
| 27 (20%)
|
Dyspnea
| NA
| 30 (27%)
| 23 (12%)
| NA
|
Supraventricular tachycardia
| 1 (1%)
| NA
| NA
| NA
|
Table 2: Possible mechanisms of Ibr-related CT
| |||
Protein
| Relation to BCR signaling
| Proposed mechanism
| Clinical CT
|
Phosphatidylinositol 3-kinase (PI3K)
| Upstream activator and downstream substrate of BTK
| Alter gene expression in ventricular tissue; Compromised regulation of autonomic calcium oscillations in cardiac cells to alter automaticity
| AF, Hemodynamic compromise, Bradycardia
|
Heat shock protein 70
| Decreased HSP 70 levels in response to attenuated PI3K activity
| Compromised role in cardiac remodeling under pressure overload or stress
| AF, hypertension
|
Phospholipase C gamma 2 (PLCγ-2)
| Downstream protein activated by BTK in BCR signaling
| Attenuated activation of PLCγ-2 compromises calcium signaling
| AF, cardiac arrhythmia
|
Table 3: Penn recommendations for management of Ibr treated patients with CT
| |
AF
| Exclude hyperthyroidism Consider Ibr dose reduction Rate control beta or calcium channel blocker. Start at low dose, uptitrate to HR < 100. If limited by hypotension, consider digoxin CVA Prevention with anticoagulation based on CHA2DS2-VASC score
|
HTN
| ACE inhibitors and/or calcium channel blockers as first line
|
Bradycardia
| Differentiate whether pt is symptomatic If asymptomatic and HR increases appropriately with exertion, no further evaluation or treatment necessary Avoid negative chronotropic medications
|
Disclosures: Schuster: Novartis: Research Funding ; Gilead: Research Funding ; Janssen: Research Funding ; Hoffman-LaRoche: Research Funding ; Celgene: Consultancy , Research Funding ; Pharmacyclics: Consultancy , Research Funding ; Genentech: Consultancy ; Nordic Nanovector: Membership on an entity’s Board of Directors or advisory committees . Svoboda: Seattle Genetics: Research Funding ; Celgene: Research Funding ; Immunomedics: Research Funding ; Celldex: Research Funding . Rago: Gilead Sciences: Speakers Bureau ; AbbVie: Membership on an entity’s Board of Directors or advisory committees . Mato: Genentech: Consultancy ; Gilead: Consultancy , Research Funding ; Celgene Corporation: Consultancy , Research Funding ; TG Therapeutics: Research Funding ; Pronai Pharmaceuticals: Research Funding ; Pharmacyclics: Consultancy , Research Funding ; AbbVie: Consultancy , Research Funding .
See more of: Health Services and Outcomes Research – Malignant Diseases
See more of: Oral and Poster Abstracts
*signifies non-member of ASH